Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 81,104 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Citius Pharmaceuticals Inc | CTXR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.1372 | 16.81% | 0.9534 | 07:19:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.8162 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 250 | 81,104 | - | 0.60 - 1.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:19:55 | formt | 520 | $ 0.9534 | USD |
Citius Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 130.46M | 159.09M | - | 0 | -33.69M | -0.21 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Citius Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTXR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.87 | 0.8898 | 0.7001 | 0.7950193 | 679,781 | 0.0834 | 9.59% |
| 1 Month | 0.779 | 1.07 | 0.7001 | 0.8929955 | 891,152 | 0.1744 | 22.39% |
| 3 Months | 0.63 | 1.07 | 0.60 | 0.7862379 | 720,953 | 0.3234 | 51.33% |
| 6 Months | 0.734 | 1.07 | 0.60 | 0.7754814 | 653,973 | 0.2194 | 29.89% |
| 1 Year | 1.67 | 1.70 | 0.60 | 1.03 | 1,050,514 | -0.7166 | -42.91% |
| 3 Years | 1.69 | 4.56 | 0.60 | 1.97 | 2,004,524 | -0.7366 | -43.59% |
| 5 Years | 1.12 | 4.56 | 0.40 | 1.85 | 2,355,509 | -0.1666 | -14.88% |
Citius Pharmaceuticals Description
| Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. |
